1990
DOI: 10.1016/0014-2999(90)93628-4
|View full text |Cite
|
Sign up to set email alerts
|

Cardiovascular effects of NKH477, a novel potent water-soluble forskolin derivative

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

1993
1993
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(8 citation statements)
references
References 0 publications
0
8
0
Order By: Relevance
“…Although the biological profile of forskolin is characterized by various pharmacological properties such as the positive inotropic, hypotensive, bronchospasmolytic and antiglaucoma activities that have been proved in vitro and in vivo using mainly laboratory animals and few humans, forskolin has not been available as an approved drug due to its low water solubility (ca. 0.001 %) [212] and low oral activity that limit its clinical usage as an intravenous formulation and an oral one, respectively [213], as well as the concern that forskolin as a nonspecific adenylyl cyclase activator may be too toxic for clinical use. Forskolin has, therefore, been considered as a useful prototype for the development of similar agents with better water solubility and more selective effects on adenylyl cyclase types.…”
Section: Second Generation Forskolin Derivativesmentioning
confidence: 99%
See 1 more Smart Citation
“…Although the biological profile of forskolin is characterized by various pharmacological properties such as the positive inotropic, hypotensive, bronchospasmolytic and antiglaucoma activities that have been proved in vitro and in vivo using mainly laboratory animals and few humans, forskolin has not been available as an approved drug due to its low water solubility (ca. 0.001 %) [212] and low oral activity that limit its clinical usage as an intravenous formulation and an oral one, respectively [213], as well as the concern that forskolin as a nonspecific adenylyl cyclase activator may be too toxic for clinical use. Forskolin has, therefore, been considered as a useful prototype for the development of similar agents with better water solubility and more selective effects on adenylyl cyclase types.…”
Section: Second Generation Forskolin Derivativesmentioning
confidence: 99%
“…Further synthetic and structure-activity studies, such as the introduction of water-soluble substituents onto forskolin, were carried out, and of the active analogues produced, the 6-(3-dimethylaminopropionyl) forskolin hydrochloride (NKH477) (79) (see Fig. 7 in part 1) was found to be one of the more potent water-soluble forskolin derivatives [213,214,216,217]. NKH477, like forskolin, was also found to stimulate adenylyl cyclase directly and produce various cAMP-dependent pharmacological effects, for example, on cardiovascular, respiratory, renal, and immune systems [92,[218][219][220][221][222][223].…”
Section: Second Generation Forskolin Derivativesmentioning
confidence: 99%
“…Studies carried out using one hundred samples belonging to species of Plectranthus and Orthosiphon of the sub family Ocimoideae at Japan also revealed the absence of forskolin in all the samples. Second generation forskolin derivatives viz., 5-6-deoxy-7-deacetyl-7-methyl amino carbon forskolin (HIL568), a potential anti glaucoma agent and 6-(3-dimethylamino propionyl) forskolin hydrochloride (NKH477), a potential cardio tonic agent were developed (Hosono et al,1990). Newer compounds are being identified from the root extracts of P. forskohlii.…”
Section: Phytochemical Properties Of P Forskohliimentioning
confidence: 99%
“…Water-soluble aminoacylforskolin analogs, for instance, 6-(piperidinoacetyl)-7-deacetylforskolin hydrochloride (HL 706) (Figure 2; 28) and 6-(3-dimethylaminopropionyl)forskolin hydrochloride (NKH 477) (Figure 2; 29) which exhibited the desired biochemical and cardiovascular profile in in vitro and in vivo animal studies, were identified. The considerations which led the group at Nippon Kayaku Ltd., Japan to the selection of NKH 477 for clinical studies, currently in progress in Japan, to evaluate it for the treatment of heart failure have been adequately described (29).…”
Section: Forskolin-derived Compound Hil 568: a Potential Anti-glaucommentioning
confidence: 99%